Sands Active Private Limited, a member of the Melwa conglomerate, participated in the 15th edition of the Medicare International Healthcare Exhibition 2026, held at BMICH Colombo, where it showcased a range of pharmaceutical products to visitors from across the country.
During the exhibition, company representatives also conducted awareness sessions aimed at educating the public on the benefits and proper use of its medicines. The company’s stall attracted significant attention throughout the event, with strong demand recorded for its paracetamol product, Meldol.
Recognised as Sri Lanka’s leading healthcare exhibition, Medicare 2026 brought together key stakeholders from across the healthcare industry, providing a platform to showcase the latest developments in healthcare services, medical technology, wellness, and medical tourism. This year’s event featured more than 150 stalls representing both local and international exhibitors.
Founded in 2018 under the Melwa Group—Sri Lanka’s premier steel manufacturing conglomerate—Sands Active focuses on the production and distribution of high-quality pharmaceutical products, including oral tablets, capsules, and injectables for the local market.
The company is committed to improving accessibility and affordability of healthcare products while maintaining strict quality standards. Its manufacturing processes comply with both local and international regulatory requirements, including World Health Organisation guidelines and EU-GMP standards.
In addition, Sands Active’s products are certified by the National Medicines Regulatory Authority, reinforcing its commitment to safety, quality, and compliance.
Tesla in discussions with Chinese suppliers for $2.9 billion solar equipment deal, sources say
Tesla is reportedly planning to purchase around $2.9 billion worth of equipment for manufacturing solar panels and cells from Chinese suppliers, including Suzhou Maxwell Technologies, according to people familiar with the matter.
The initiative is part of CEO Elon Musk’s broader push to significantly expand solar capacity in the United States, with plans targeting up to 100 gigawatts of solar energy deployment. Musk has previously suggested that solar power could potentially meet the entire electricity demand of the U.S., including rising consumption from data centres.
Suzhou Maxwell Technologies, a major producer of screen-printing equipment used in solar cell manufacturing, is among the leading candidates to supply machinery for the project. The company has reportedly been seeking export approval from China’s commerce ministry. Other potential suppliers include Shenzhen S.C New Energy Technology and Laplace Renewable Energy Technology.
According to sources, some of the estimated 20 billion yuan ($2.9 billion) worth of equipment—particularly screen-printing production lines—will require regulatory approval from Chinese authorities. The delivery timeline and approval process remain uncertain.
The suppliers have been asked to deliver equipment before the autumn, with shipments expected to go to Texas. The solar capacity is primarily intended to support Tesla’s own operations, with additional usage planned for SpaceX satellite infrastructure, the sources said.
The development highlights ongoing global supply chain dependencies in clean energy manufacturing, even as the United States seeks to expand domestic production capabilities.
Neither Tesla nor the companies involved, nor China’s commerce ministry, have publicly commented on the matter.
Sands Active presents its pharmaceutical range at the Medicare 2026 Exhibition
